Vertex Pharmaceuticals’ Revenue Forecast Tops Expectations

Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ wants. 

The company said it anticipates 2025 revenue of $11.75 billion to $12 billion, representing nearly 20% spread from 2024 at the midpoint and well above analysts’ projections compiled by Visible Alpha. 

Vertex’s fourth-quarter receipts of $2.91 billion was up 16% year-over-year and also exceeded the analyst consensus. Adjusted earnings of $1.04 billion, or $3.98 per apportionment, fell from $1.1 billion, or $4.20 per share, a year earlier, slightly short of estimates. Vertex spiculate to an increase in operating expenses, lower interest income, and higher tax expenses for the decline.

The results come after the Commons and Drug Administration recently approved Vertex Pharmaceuticals’ non-opioid painkiller Journavx, a twice-daily pill for the treatment of shooting pain. CEO Reshma Kewalramani called Journavx “the first new class of pain medicine approved in more than 20 years.”

Pay outs of Vertex Pharmaceuticals were little changed in extended trading Monday following the release. The stock has gained 12% terminated the past 12 months through Monday’s close.